zelnecirnon

Zelnecirnon is an orally bioavailable small molecule antagonist of the C-C motif chemokine receptor 4 (CCR4). It was developed by RAPT Therapeutics for the treatment of inflammatory diseases such as atopic dermatitis and asthma. By inhibiting CCR4, zelnecirnon blocks the recruitment of Th2 inflammatory immune cells into inflamed tissues. The drug advanced to Phase II clinical trials but was discontinued after a serious adverse event (severe liver injury requiring transplant) led to a clinical hold by the FDA. No other significant safety signals were observed in other trial participants or nonclinical studies[1][3][5][6].

Other names

2366152-15-8Cyclobutanecarboxylic acid, 3-[(3R)-3-[1-[5-chloro-4-[[(1R)-1-(2,4-dichlorophenyl)ethyl]amino]-6-methylpyrimidin-2-yl]azetidin-3-yl]piperidin-1-yl]-1-methylcyclobutane-1-carboxylic acid